ELV

ANALYST NOTE: ELV (Elevance Health Inc.) Date: 2026-06-13 Current Price: $388.50

1. Structural Readiness

• Aggressive/Pre-Breakout Entry: Not actionable on setup alone; requires confirmation.
• Current Price: $388.50
• Extension: Not applicable (price is within the forming range, not extended above a breakout).
• ATR Context: Current ATR is 2.8% (productive). This sits within the "productive" range, suggesting volatility is sufficient for position sizing but not in the "extreme" (>8%) or "weak" (<2.5%) buckets.

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED
• Macro Thesis Status: NONE NAMED
• Analysis: As of 2026-06-13, there is no named secular thesis driving this specific trade. The conviction must be derived entirely from the quality of the technical setup (the forming coil) and the immediate business fundamentals disclosed in the most recent earnings and filings. We are not assigning a macro narrative (e.g., "healthcare reform beneficiary" or "demographic super-cycle") to this trade; we are judging the name on its ability to execute its current guidance and the structural integrity of its price action.

3. Business Overview

Elevance Health Inc. operates as a major health benefits organization, serving approximately 45.4 million medical members as of March 31, 2026. The company functions as a Blue Cross licensee in key markets including California, New York, Ohio, and others, offering a broad spectrum of managed care risk-based plans across Individual, Employer Group, Medicaid, and Medicare markets.

Key Business Components (as of source dates ≤ 2026-06-13):

• Membership Growth: The company ended March 2026 with 45.4 million members, an increase of nearly 200,000 from year-end, driven by growth in commercial fee-based membership and higher enrollment in Individual ACA plans (E6, E9).
• Operational Efficiency: Management reports that specific integrated programs (pharmacy, specialty care, behavioral health) have reduced hospital readmissions by 20% and generated over 10% savings on post-acute care (E5).
• Pharmacy Services: Through its subsidiary CarelonRx, the company offers pharmacy services. Notably, core pharmacy services are delegated to CVS Health Corporation (CaremarkPCS) under an agreement extending through December 31, 2027 (E12, E21).
• Government Exposure: Approximately 32% of total consolidated revenues were generated from U.S. government agencies in 2025 (E18).
• Strategic Shifts: Management announced that in 2026, the company will no longer offer Medicare Part D plans (E22).

4. Archetype and Conviction Stack

• Archetype: Deep Value Recovery
• Rationale: The archetype fits based on the company's recent guidance revisions and margin trajectory. Management has raised full-year adjusted diluted EPS guidance to at least $26.75 for 2026, signaling a recovery from prior cost pressures. The company is targeting an operating margin of at least 2% in 2026, moving from a previously negative outlook (approx. -1.75% full-year 2026 outlook mentioned in E4, though E3 suggests a positive 2% target, indicating a management expectation of improvement or a specific segment focus).
• Valuation Context: The financial spine indicates a forward consensus EPS of $26.85 for FY1 and $29.24 for FY2 (E27).
• Conviction Stack:
• Thesis Strength: Low (Tactical only, no macro thesis).
• Evidence Quality: High. Recent earnings (April 22, 2026) provide specific, quantitative guidance on EPS, membership, and margins.
• Structural Quality: Moderate. The "Deep Value Recovery" archetype is supported by the guidance raise, but the company faces regulatory headwinds (CMS sanctions timeline) and pharmacy benefit manager (PBM) reforms.
• Setup Readiness: Partial. The coil is forming, which is a positive structural signal, but the breakout has not occurred.
• Rerating Potential: Dependent on the successful execution of the 2026 margin targets and the resolution of the CMS compliance timeline.

5. Invalidations, Strengths, and Gaps

• Gaps in Evidence:
• Breakout Confirmation: The current price action is "forming," meaning the breakout level is unknown.
• PBM Reform Impact: While E16 mentions PBM reforms effective 30 months after enactment (Feb 2026), the specific financial impact on Elevance's 2026 or 2027 earnings is not quantified in the provided evidence.
• Sanctions Resolution: The evidence notes a compliance timeline until July 31, 2026, but does not confirm the outcome of these steps.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Raised full-year adjusted EPS guidance to at least $26.75; membership growth of nearly 200,000 in Q1 2026; forming coil structure with price holding above structural support. Key risks: CMS sanctions compliance deadline of July 31, 2026; potential negative impact from new PBM rebate reforms; current setup is forming, not confirmed breakout. Sizing hint: Position size should be conservative given the "forming" status and regulatory overhang; wait for breakout confirmation for full sizing. Expected path: Management expects to achieve 2% operating margin in 2026 and 12% EPS growth in 2027; price likely to consolidate until breakout or regulatory clarity. Expected horizon: 3 to 6 months for setup confirmation or regulatory resolution.